tiprankstipranks
Rigel Pharmaceuticals: NCCN adds REZLIDHIA to clinical practice guidelines
The Fly

Rigel Pharmaceuticals: NCCN adds REZLIDHIA to clinical practice guidelines

Rigel Pharmaceuticals announced that REZLIDHIA has been added by the National Comprehensive Cancer Network to the latest NCCN Clinical Practice Guidelines in Oncology for acute myeloid leukemia. REZLIDHIA is now included as a recommended targeted therapy for adult patients with relapsed/refractory AML with isocitrate dehydrogenase-1 mutation.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on RIGL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles